Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Howard Pringle is active.

Publication


Featured researches published by J. Howard Pringle.


Cancer Cell | 2013

A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma

Julie Caramel; Eftychios Papadogeorgakis; Louise Hill; Gareth J. Browne; Geoffrey Richard; Anne Wierinckx; Gerald Saldanha; Joy Osborne; Peter E. Hutchinson; Gina Tse; Joël Lachuer; Alain Puisieux; J. Howard Pringle; Stéphane Ansieau; Eugene Tulchinsky

Aberrant expression of embryonic epithelial-mesenchymal transition-inducing transcription factors (EMT-TFs) in epithelial cells triggers EMT, neoplastic transformation, stemness, and metastatic dissemination. We found that regulation and functions of EMT-TFs are different in malignant melanoma. SNAIL2 and ZEB2 transcription factors are expressed in normal melanocytes and behave as tumor-suppressor proteins by activating an MITF-dependent melanocyte differentiation program. In response to NRAS/BRAF activation, EMT-TF network undergoes a profound reorganization in favor of TWIST1 and ZEB1. This reversible switch cooperates with BRAF in promoting dedifferentiation and neoplastic transformation of melanocytes. We detected EMT-TF reprogramming in late-stage melanoma in association with enhanced phospho-ERK levels. This switch results in E-cadherin loss, enhanced invasion, and constitutes an independent factor of poor prognosis in melanoma patients.


International Journal of Cancer | 2004

High BRAF mutation frequency does not characterize all melanocytic tumor types.

Gerald Saldanha; David Purnell; Alan Fletcher; Linda Potter; Angela K. Gillies; J. Howard Pringle

Cutaneous melanoma (CM) is the most lethal form of skin cancer. Along with some benign melanocytic tumors, the majority shows BRAF or NRAS mutation, but it is not known whether these are essential to all forms of melanocytic neoplasia. We screened 79 melanocytic tumors of different types for BRAF and NRAS mutations and looked at MAPK pathway activity using immunohistochemistry in a subset. Significant differences in BRAF exon 15 mutation frequency were found: 14/16 (87.5%) in common acquired naevi (CANs), 9/12 (75%) in CMs, 0/26 in Spitz naevi and 3/25 (12%) in blue naevi (p < 0.01). We looked at whether Spitz and blue naevi showed a compensatory increase in BRAF exon 11 and/or NRAS exons 1 and 2 mutations to account for the low BRAF exon 15 mutation frequency. NRAS mutations were found in only 1/16 (6.3%) Spitz naevi and 0/15 blue naevi. In addition, NRAS mutations were found in 2/11 (18.2%) CANs and 3/12 (25%) CMs. None of the tumors showed BRAF exon 11 mutations. Despite their low combined BRAF and NRAS mutation frequency, Spitz naevi showed strong MAPK pathway activation as measured by cytoplasmic expression of dually phosphorylated ERK1/2, while blue naevi had weak pathway activation. We conclude that BRAF and NRAS mutations are not necessary for melanocytic tumor development and that some types of tumor must arise by alternative mechanisms.


Clinical Cancer Research | 2008

WNT5A expression increases during melanoma progression and correlates with outcome.

Philip D. Da Forno; J. Howard Pringle; P.E. Hutchinson; Joy Osborn; Qiang Huang; Linda Potter; Rachael A. Hancox; A. Fletcher; Gerald Saldanha

Purpose: Wnt ligands play a major role in development and are important in cancer. Expression microarray analysis correlates one member of this family, WNT5A, to a subclass of melanomas with increased motility and invasion. There are no large studies of clinical samples primarily addressing the importance of WNT5A in melanoma progression or outcome. Therefore, this study aimed to assess the protein expression of WNT5A during melanoma progression and its effect on outcome. Experimental Design: Expression of WNT5A was determined in a series of 59 primary melanomas with matched metastases. To provide a benchmark of progression against which to assess WNT5A, expression of p16ink4a was analyzed, as this has been previously well documented in melanoma. The effect of WNT5A protein expression on outcome was assessed in 102 melanomas. Results: Cytoplasmic WNT5A showed a trend of increasing expression with melanoma progression (P = 0.013), whereas there was diminishing p16ink4a expression (P = 0.006). Nevi showed relatively strong WNT5A expression. Strong cytoplasmic WNT5A was an independent risk factor for reduced metastasis-free and overall survival in multivariate analysis (P = 0.001 and 0.003, respectively). Conclusion: Cytoplasmic WNT5A increases with melanoma progression and strong expression is associated with poor outcome.


Cancer and Metastasis Reviews | 2010

Expression of tenascin-C and its isoforms in the breast

David S. Guttery; Jacqueline A. Shaw; Kirsty Lloyd; J. Howard Pringle; Rosemary A. Walker

Tenascin-C (TNC) is an extracellular matrix glycoprotein which is frequently up-regulated in a variety of pathological conditions including chronic inflammation and cancer. TNC has been implicated in the modulation of cell migration, proliferation, invasion and angiogenesis. Multiple isoforms of TNC can be generated through the alternative splicing of nine exons located in the fibronectin type III region of the molecule. The profile of isoforms expressed differs between cancers and normal breast, with the fully truncated TNC isoform being predominant in normal and benign tissues and higher molecular weight isoforms induced predominantly in cancer. The addition of extra domains within the fibronectin type III repeat domain greatly affects TNC function with multiple exon combinations available for splicing. Exons 14 and 16 are considered to be tumour-associated and have been shown to affect breast cell line invasion and growth in vitro to a greater extent than the full-length TNC isoform. This mini review will provide a summary of the literature to date regarding the expression of TNC isoforms in the breast and also discuss more recent developments in the field regarding exon AD1.


Journal of Investigative Dermatology | 2013

Plasma MicroRNA-21 Is Associated with Tumor Burden in Cutaneous Melanoma

Gerald Saldanha; Linda Potter; Priya Shendge; Joy Osborne; Steve Nicholson; NgiWieh Yii; Sanjay Varma; Mi Aslam; Shona Elshaw; Eftychios Papadogeorgakis; J. Howard Pringle

Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; miRNA, microRNA


web science | 2001

Specific Inhibition of Estrogen Receptor Alpha Function by Antisense Oligodeoxyribonucleotides

Anthony H. Taylor; J. Howard Pringle; Stephen C. Bell; Farook Al-Azzawi

We have tested the effect of a range of antisense oligodeoxyribonucleotides (ODN) directed against the human estrogen receptor alpha (ERalpha) on ERalpha protein expression and function. Antisense ERalpha ODN transfected into the ERalpha-positive human breast carcinoma cell line MCF7-K2 showed variable responses dependent on the oligo used. The most active antisense ODN (oligo 7) decreased the levels of ERa protein by 61% as measured by Western blot analysis. Exogenous 17beta-estradiol (17beta-E2), but not 17alpha-E2, augmented this effect, with a threshold effect at 10(-8) M 17beta-E2. The inhibitory effect of antisense ERa oligo 7 was confirmed by measurement of functional ERalpha protein. 3H-17beta-E2 binding to MCF7 cell extracts was inhibited to approximately 40% of control values in the presence of oligo 7. Antisense-transfected MCF7-K2 cell cultures produced a further 30% binding reduction in the presence of exogenous 17beta-E2. An inhibitory effect on 17beta-E2-dependent cell function was confirmed by the demonstration that ERalpha oligo 7-transfected MCF7-K2 cells failed to exhibit 17beta-E2-stimulated cell proliferation. Exogenous 17beta-E2 enhanced the inhibitory effect of the antisense ODN by increasing ODN transfection efficiency but without ERalpha catabolism via the proteosomal pathway, suggesting an effect of 17beta-E2 on the plasma membrane and the existence of different ERalpha degradation pathways in the MCF7-K2 cell subclone. As 17beta-E2 had no effect on ERalpha protein degradation, we conclude that the observed reduction of ERalpha protein levels is due solely to the presence of the antisense ERalpha ODN. Antisense ERalpha ODN molecules, therefore, may form the basis of effective therapies against ERalpha-dependent malignancies.


Histopathology | 2012

Prognostic tissue markers in melanoma

David Moore; J. Howard Pringle; Gerald Saldanha

Moore D A, Pringle J H & Saldanha G S 
(2012) Histopathology 60, 679–689
Prognostic tissue markers in melanoma


The Journal of Pathology | 2000

Inactive matrix metalloproteinase 2 is a normal constituent of human glomerular basement membrane. An immuno‐electron microscopic study

Sawsan M Jalalah; Peter N. Furness; Gordon Barker; Mark Thomas; Leon L. Hall; Gareth R. Bicknell; Jacqui A. Shaw; J. Howard Pringle

Remodelling of the extracellular matrix requires tight control not only of matrix synthesis, but also of matrix degradation. Control of matrix degradation is achieved mainly through the matrix metalloproteinase (MMP) enzymes. In the glomerulus, MMP‐2 and MMP‐9 are believed to be particularly important, as they have activity against type IV collagen. This study has demonstrated by immuno‐electron microscopy that most of the immunoreactivity for MMP‐2 in the normal glomerulus is located within the glomerular basement membranes and mesangial matrix. mRNA for MMP‐2 is also detectable in normal glomeruli, but the other main gelatinase, MMP‐9, could not be localized by immuno‐electron microscopy. In the normal glomerulus, it seemed likely that MMP‐2 is present in an inactive form. To confirm this, in situ zymography was carried out using frozen sections of normal kidney. Baseline activity of normal kidney was relatively weak, but this was dramatically increased by chemical activation of metalloproteinases. The results imply that MMP‐2, in an inactive form, is a normal constituent of the extracellular matrix and glomerular basement membranes. Activation would presumably render the matrix ‘self‐degrading’; membrane‐bound MMPs (MT‐MMPs) seem particularly likely to be involved in leukocyte penetration of basement membranes in inflammation. Copyright


The Journal of Molecular Diagnostics | 2013

Accurate Detection of Copy Number Changes in DNA Extracted from Formalin-Fixed, Paraffin-Embedded Melanoma Tissue Using Duplex Ratio Tests

David Moore; Gerald Saldanha; Abdlrzag Ehdode; Linda Potter; Lovesh Dyall; Danielle Bury; J. Howard Pringle

A minority of melanocytic lesions cannot confidently be classified as benign or malignant on histopathological examination, causing diagnostic uncertainty. DNA copy number changes can be used to distinguish nevi from melanoma, although the use of FFPE tissue can pose technical challenges. DNA copy number assays, called duplex ratio tests, have been developed with duplex real-time PCR, using a simple method with potential for high throughput. Five duplex ratio test assays targeting loci with common DNA copy number changes in melanoma were designed and tested using DNA extracted from FFPE samples microdissected from melanoma, common nevi, benign tonsil (10 each), and two melanoma cell lines. The assays proved accurate when DNA extracted from fresh and FFPE melanoma cell lines were compared (intraclass correlation coefficient, 0.99) and gave precise results when repeated on DNA from FFPE tissue (intraclass correlation coefficient range, 0.90 to 0.96). In combination, duplex ratio test values from three of the assays distinguished between the nevi and melanomas with 100% sensitivity (95% CI, 69.1% to 100%) and 100% specificity (95% CI, 69.1% to 100%). Duplex ratio test assays have been shown to be accurate and precise and can distinguish melanomas from common nevi using DNA from FFPE tissue. Appropriately designed assays could have value in assessment of other cancers.


Journal of Molecular Neuroscience | 2003

Nuclear immunostaining in rat neuronal cells using two anti-kir2.2 ion channel polyclonal antibodies

Anthony H. Stonehouse; Blair D. Grubb; J. Howard Pringle; Robert I. Norman; Peter R. Stanfield; William J. Brammar

The inwardly rectifying potassium ion channel Kir2.2 has recently been demonstrated to have nuclear and plasma membrane subcellular localization. Nuclear expression of Kir2.2 is controversial, as a functional role for Kir2.0 potassium channels in the nucleus has not been investigated. However, in this report we have demonstrated Kir2.2 nuclear localization in sections of rat hindbrain and dorsal root ganglia tissue, using two anti-Kir2.2 polyclonal antisera with different epitope specificities. These data confirm nuclear localization and are suggestive of new functions of Kir2.0 potassium ion channels in the nucleus.

Collaboration


Dive into the J. Howard Pringle's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Linda Potter

University of Leicester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Moore

University of Leicester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joy Osborne

University Hospitals of Leicester NHS Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge